Comparative study on T-3262 (tosufloxacin tosilate) and ofloxacin in respiratory tract infection by double-blind method

Ippei Fujimori; Akira Saito; Ichiro Nakayama; Masumi Tomisawa; Kazuo Takebe; Mitsuo Nakamura; Takahiko Kawagishi; Tadashi Miyazawa; Toyokazu Tamura; Katsumi Endo; Tamotsu Takishima; Ruriko Mamune; Kiyoshi Konno; Kotaro Oizumi; Seiichi Aonuma; Akira Watanabe; Yutaka Tokue; Izumi Hayashi; Shinji Okui; Toshio Fukui; Shinjiro Kato; Osamu Hosono; Toru Abe; Toshihiko Haga; Harumi Shishido; Hiroyuki Kobayashi; Shin Kawai; Hiroaki Takeda; Masahide Kawahira; Tadashi Miyahara; Jingoro Shimada; Junzaburo Kabe; Koichiro Kudo; Yoshio Sakamoto; Kaoru Shimada; Yasuyuki Sano; Yasufumi Miyamoto; Koji Yoshimoto; Hideo Ikemoto; Kazuyoshi Watanabe; Masayoshi Inagaki; Hajime Orimo; Yoshinosuke Fukuchi; Minoru Yamaoka; Mitsuo Honma; Takashi Kawai; Atsushi Ajisawa; Akio Onaka; Fuyuhiko Higashi; Kazumi Arikawa; Tatsuo Kato; Miyoko Kuramoto; Hiroichi Tanimoto; Koichiro Nakata; Naohiko Chonabayashi; Yoshitaka Nakamori; Tatsuo Nakatani; Takashi Inamatsu; Makiko Fukayama; Kentaro Watanabe; Masaru Koyama; Yoshio Uzuka; Shoichiro Irimajiri; Yasuo Matsuoka; Mitsuo Obana; Takeshi Mitsui; Takao Okubo; Hirotada Ikeda; Masanori Matsumura; Hiroshi Takahashi; Fumio Matsumoto; Iwao Sakurai; Kazufuto Fukaya; Shigeki Odagiri; Kaneo Suzuki; Kohu Murohashi; Keiichiro Matsunaga; Hiroyuki Numata; Izumi Oyama; Shunichi Ishii; Masaaki Arakawa; Koichi Wada; Osamu Sekine; Nobuki Aoki; Kaoru Oyama; Atsuhiko Sato; Masahiko Okano; Wataru Sugiura; Akira Yamazaki; Takayoshi Watanabe; Toshihiko Takeuchi; Masahito Kato; Kunio Nanjo; Tatsuo Satake; Kenzo Takagi; Kenichi Yamaki; Hideo Gonda; Yasunobu Noda; Fumiyuki Kuze; Takuya Kurasawa; Takako Murayama; Eisaku Tanaka; Takakazu Sugita; Fumio Miki; Yoshiyasu Ikuno; Eiji Inoue; Akihito Murata; Shinichi Tanizawa; Kazuo Sakamoto; Akira Tahara; Yoshio Kawase; Kojiro Yasunaga; Seibun Yonezu; Nobuhiro Narita; Masayoshi Sawaki; Keiichi Mikasa; Rinzo Soejima; Yoshihito Niki; Yoshikazu Tasaka; Toshio Kishimoto; Toshiharu Matsushima; Michifumi Adachi; Osamu Kurimura; Hideo Sasaki; Hirofumi Fukuhara; Takao Sasaki; Yukio Matsumoto; Yoshiro Sawae; Atsushi Shinoda; Tsuneo Ishibashi; Masahiro Takamoto; Hozumi Yamada; Osamu Katoh; Kohei Hara; Masaki Hirota; Keizo Yamaguchi; Shigeru Kohno; Toshiaki Hayashi; Akira Yasuoka; Kazuo Sasayama; Makoto Ishizaki; Takashi Ide; Hiroko Nakazato; Oe Toshiyuki; Keizo Matsumoto; Atsushi Takahashi; Sukuro Araki; Masayuki Ando; Moritaka Suga; Kiyoshi Shima; Shinobu Takenaka; Yasutsugu Fukuda; Haruhiko Tokuomi; Masaru Nasu; Hideaki Shigeno; Jun Goto; Takayoshi Tashiro

doi:10.11250/chemotherapy1953.37.1086

Comparative study on T-3262 (tosufloxacin tosilate) and ofloxacin in respiratory tract infection by double-blind method

Ippei Fujimori, Akira Saito, Ichiro Nakayama, Masumi Tomisawa, Kazuo Takebe, Mitsuo Nakamura, Takahiko Kawagishi, Tadashi Miyazawa, Toyokazu Tamura, Katsumi Endo, Tamotsu Takishima, Ruriko Mamune, Kiyoshi Konno, Kotaro Oizumi, Seiichi Aonuma, Akira Watanabe, Yutaka Tokue, Izumi Hayashi, Shinji Okui, Toshio FukuiShinjiro Kato, Osamu Hosono, Toru Abe, Toshihiko Haga, Harumi Shishido, Hiroyuki Kobayashi, Shin Kawai, Hiroaki Takeda, Masahide Kawahira, Tadashi Miyahara, Jingoro Shimada, Junzaburo Kabe, Koichiro Kudo, Yoshio Sakamoto, Kaoru Shimada, Yasuyuki Sano, Yasufumi Miyamoto, Koji Yoshimoto, Hideo Ikemoto, Kazuyoshi Watanabe, Masayoshi Inagaki, Hajime Orimo, Yoshinosuke Fukuchi, Minoru Yamaoka, Mitsuo Honma, Takashi Kawai, Atsushi Ajisawa, Akio Onaka, Fuyuhiko Higashi, Kazumi Arikawa, Tatsuo Kato, Miyoko Kuramoto, Hiroichi Tanimoto, Koichiro Nakata, Naohiko Chonabayashi, Yoshitaka Nakamori, Tatsuo Nakatani, Takashi Inamatsu, Makiko Fukayama, Kentaro Watanabe, Masaru Koyama, Yoshio Uzuka, Shoichiro Irimajiri, Yasuo Matsuoka, Mitsuo Obana, Takeshi Mitsui, Takao Okubo, Hirotada Ikeda, Masanori Matsumura, Hiroshi Takahashi, Fumio Matsumoto, Iwao Sakurai, Kazufuto Fukaya, Shigeki Odagiri, Kaneo Suzuki, Kohu Murohashi, Keiichiro Matsunaga, Hiroyuki Numata, Izumi Oyama, Shunichi Ishii, Masaaki Arakawa, Koichi Wada, Osamu Sekine, Nobuki Aoki, Kaoru Oyama, Atsuhiko Sato, Masahiko Okano, Wataru Sugiura, Akira Yamazaki, Takayoshi Watanabe, Toshihiko Takeuchi, Masahito Kato, Kunio Nanjo, Tatsuo Satake, Kenzo Takagi, Kenichi Yamaki, Hideo Gonda, Yasunobu Noda, Fumiyuki Kuze, Takuya Kurasawa, Takako Murayama, Eisaku Tanaka, Takakazu Sugita, Fumio Miki, Yoshiyasu Ikuno, Eiji Inoue, Akihito Murata, Shinichi Tanizawa, Kazuo Sakamoto, Akira Tahara, Yoshio Kawase, Kojiro Yasunaga, Seibun Yonezu, Nobuhiro Narita, Masayoshi Sawaki, Keiichi Mikasa, Rinzo Soejima, Yoshihito Niki, Yoshikazu Tasaka, Toshio Kishimoto, Toshiharu Matsushima, Michifumi Adachi, Osamu Kurimura, Hideo Sasaki, Hirofumi Fukuhara, Takao Sasaki, Yukio Matsumoto, Yoshiro Sawae, Atsushi Shinoda, Tsuneo Ishibashi, Masahiro Takamoto, Hozumi Yamada, Osamu Katoh, Kohei Hara, Masaki Hirota, Keizo Yamaguchi, Shigeru Kohno, Toshiaki Hayashi, Akira Yasuoka, Kazuo Sasayama, Makoto Ishizaki, Takashi Ide, Hiroko Nakazato, Oe Toshiyuki, Keizo Matsumoto, Atsushi Takahashi, Sukuro Araki, Masayuki Ando, Moritaka Suga, Kiyoshi Shima, Shinobu Takenaka, Yasutsugu Fukuda, Haruhiko Tokuomi, Masaru Nasu, Hideaki Shigeno, Jun Goto, Takayoshi Tashiro

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

Abstract

We compared the clinical efficacy, safety and utility of T-3262 (tosufloxacin tosilate), a new derivative pyridonecarboxylic acid, with those of ofloxacin (OFLX) in patients with respiratory tract infection (RTI) by double-blind study. RTI included in the protocol were bacterial pneumonia and chronic respiratory tract infection. The drug was given orally for a fixed period of 14 days and the daily dosage was fixed at 450mg for T-3262 or 600mg for OFLX. The following results were obtained. 1. On the basis of committee judgement, the clinical efficacy rate in all cases was 82.9% for T-3262 and 82.5% for OFLX. No significant difference was observed between the two groups, not even in clinical efficacy when classified by type of disease. 2. The clinical efficacy rate judged by the doctors in charge was similar to that judged by the committee. 3. The bacteriological eradication rate of causative organisms judged by the committee was 78.6% for T-3262 and 85.1% for OFLX, without statistically significant difference. 4. With respect to the rate of improvement of clinical signs, symptoms and laboratory findings, T-3262 was superior to OFLX as to body temperature. 5. The incidence rate of side effects was 7.8% for T-3262 and 6.7% for OFLX, and there were no significant differences between the two groups. Abnormalities in laboratory findings, mainly slightly elevated serum transaminase and eosinophils, were not significantly different between the two groups. 6. The utility rate in all cases judged by the committee was 79.6% for T-3262 and 79.8% for OFLX. No significant difference between the two groups was noted. Even when classified by type of disease, there was no significant difference in utility between the two groups. 7. Neither was there any significant difference between the two groups in the utility rate when judged by the doctors in charge. 8. From our results, we consider both T-3262 (at a daily dose of 450 mg) and OFLX (at a daily dose of 600mg) to be highly useful antibacterial agents for the treatment of respiratory tract infections.

Original language	English
Pages (from-to)	1086-1118
Number of pages	33
Journal	Chemotherapy
Volume	37
Issue number	8
DOIs	https://doi.org/10.11250/chemotherapy1953.37.1086
Publication status	Published - 1989
Externally published	Yes

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.37.1086

Cite this

Fujimori, I., Saito, A., Nakayama, I., Tomisawa, M., Takebe, K., Nakamura, M., Kawagishi, T., Miyazawa, T., Tamura, T., Endo, K., Takishima, T., Mamune, R., Konno, K., Oizumi, K., Aonuma, S., Watanabe, A., Tokue, Y., Hayashi, I., Okui, S., ... Tashiro, T. (1989). Comparative study on T-3262 (tosufloxacin tosilate) and ofloxacin in respiratory tract infection by double-blind method. Chemotherapy, 37(8), 1086-1118. https://doi.org/10.11250/chemotherapy1953.37.1086

Fujimori, I, Saito, A, Nakayama, I, Tomisawa, M, Takebe, K, Nakamura, M, Kawagishi, T, Miyazawa, T, Tamura, T, Endo, K, Takishima, T, Mamune, R, Konno, K, Oizumi, K, Aonuma, S, Watanabe, A, Tokue, Y, Hayashi, I, Okui, S, Fukui, T, Kato, S, Hosono, O, Abe, T, Haga, T, Shishido, H, Kobayashi, H, Kawai, S, Takeda, H, Kawahira, M, Miyahara, T, Shimada, J, Kabe, J, Kudo, K, Sakamoto, Y, Shimada, K, Sano, Y, Miyamoto, Y, Yoshimoto, K, Ikemoto, H, Watanabe, K, Inagaki, M, Orimo, H, Fukuchi, Y, Yamaoka, M, Honma, M, Kawai, T, Ajisawa, A, Onaka, A, Higashi, F, Arikawa, K, Kato, T, Kuramoto, M, Tanimoto, H, Nakata, K, Chonabayashi, N, Nakamori, Y, Nakatani, T, Inamatsu, T, Fukayama, M, Watanabe, K, Koyama, M, Uzuka, Y, Irimajiri, S, Matsuoka, Y, Obana, M, Mitsui, T, Okubo, T, Ikeda, H, Matsumura, M, Takahashi, H, Matsumoto, F, Sakurai, I, Fukaya, K, Odagiri, S, Suzuki, K, Murohashi, K, Matsunaga, K, Numata, H, Oyama, I, Ishii, S, Arakawa, M, Wada, K, Sekine, O, Aoki, N, Oyama, K, Sato, A, Okano, M, Sugiura, W, Yamazaki, A, Watanabe, T, Takeuchi, T, Kato, M, Nanjo, K, Satake, T, Takagi, K, Yamaki, K, Gonda, H, Noda, Y, Kuze, F, Kurasawa, T, Murayama, T, Tanaka, E, Sugita, T, Miki, F, Ikuno, Y, Inoue, E, Murata, A, Tanizawa, S, Sakamoto, K, Tahara, A, Kawase, Y, Yasunaga, K, Yonezu, S, Narita, N, Sawaki, M, Mikasa, K, Soejima, R, Niki, Y, Tasaka, Y, Kishimoto, T, Matsushima, T, Adachi, M, Kurimura, O, Sasaki, H, Fukuhara, H, Sasaki, T, Matsumoto, Y, Sawae, Y, Shinoda, A, Ishibashi, T, Takamoto, M, Yamada, H, Katoh, O, Hara, K, Hirota, M, Yamaguchi, K, Kohno, S, Hayashi, T, Yasuoka, A, Sasayama, K, Ishizaki, M, Ide, T, Nakazato, H, Toshiyuki, O, Matsumoto, K, Takahashi, A, Araki, S, Ando, M, Suga, M, Shima, K, Takenaka, S, Fukuda, Y, Tokuomi, H, Nasu, M, Shigeno, H, Goto, J & Tashiro, T 1989, 'Comparative study on T-3262 (tosufloxacin tosilate) and ofloxacin in respiratory tract infection by double-blind method', Chemotherapy, vol. 37, no. 8, pp. 1086-1118. https://doi.org/10.11250/chemotherapy1953.37.1086

@article{03b2b6911f5e4ae480e35d2f424b6836,

title = "Comparative study on T-3262 (tosufloxacin tosilate) and ofloxacin in respiratory tract infection by double-blind method",

abstract = "We compared the clinical efficacy, safety and utility of T-3262 (tosufloxacin tosilate), a new derivative pyridonecarboxylic acid, with those of ofloxacin (OFLX) in patients with respiratory tract infection (RTI) by double-blind study. RTI included in the protocol were bacterial pneumonia and chronic respiratory tract infection. The drug was given orally for a fixed period of 14 days and the daily dosage was fixed at 450mg for T-3262 or 600mg for OFLX. The following results were obtained. 1. On the basis of committee judgement, the clinical efficacy rate in all cases was 82.9% for T-3262 and 82.5% for OFLX. No significant difference was observed between the two groups, not even in clinical efficacy when classified by type of disease. 2. The clinical efficacy rate judged by the doctors in charge was similar to that judged by the committee. 3. The bacteriological eradication rate of causative organisms judged by the committee was 78.6% for T-3262 and 85.1% for OFLX, without statistically significant difference. 4. With respect to the rate of improvement of clinical signs, symptoms and laboratory findings, T-3262 was superior to OFLX as to body temperature. 5. The incidence rate of side effects was 7.8% for T-3262 and 6.7% for OFLX, and there were no significant differences between the two groups. Abnormalities in laboratory findings, mainly slightly elevated serum transaminase and eosinophils, were not significantly different between the two groups. 6. The utility rate in all cases judged by the committee was 79.6% for T-3262 and 79.8% for OFLX. No significant difference between the two groups was noted. Even when classified by type of disease, there was no significant difference in utility between the two groups. 7. Neither was there any significant difference between the two groups in the utility rate when judged by the doctors in charge. 8. From our results, we consider both T-3262 (at a daily dose of 450 mg) and OFLX (at a daily dose of 600mg) to be highly useful antibacterial agents for the treatment of respiratory tract infections.",

author = "Ippei Fujimori and Akira Saito and Ichiro Nakayama and Masumi Tomisawa and Kazuo Takebe and Mitsuo Nakamura and Takahiko Kawagishi and Tadashi Miyazawa and Toyokazu Tamura and Katsumi Endo and Tamotsu Takishima and Ruriko Mamune and Kiyoshi Konno and Kotaro Oizumi and Seiichi Aonuma and Akira Watanabe and Yutaka Tokue and Izumi Hayashi and Shinji Okui and Toshio Fukui and Shinjiro Kato and Osamu Hosono and Toru Abe and Toshihiko Haga and Harumi Shishido and Hiroyuki Kobayashi and Shin Kawai and Hiroaki Takeda and Masahide Kawahira and Tadashi Miyahara and Jingoro Shimada and Junzaburo Kabe and Koichiro Kudo and Yoshio Sakamoto and Kaoru Shimada and Yasuyuki Sano and Yasufumi Miyamoto and Koji Yoshimoto and Hideo Ikemoto and Kazuyoshi Watanabe and Masayoshi Inagaki and Hajime Orimo and Yoshinosuke Fukuchi and Minoru Yamaoka and Mitsuo Honma and Takashi Kawai and Atsushi Ajisawa and Akio Onaka and Fuyuhiko Higashi and Kazumi Arikawa and Tatsuo Kato and Miyoko Kuramoto and Hiroichi Tanimoto and Koichiro Nakata and Naohiko Chonabayashi and Yoshitaka Nakamori and Tatsuo Nakatani and Takashi Inamatsu and Makiko Fukayama and Kentaro Watanabe and Masaru Koyama and Yoshio Uzuka and Shoichiro Irimajiri and Yasuo Matsuoka and Mitsuo Obana and Takeshi Mitsui and Takao Okubo and Hirotada Ikeda and Masanori Matsumura and Hiroshi Takahashi and Fumio Matsumoto and Iwao Sakurai and Kazufuto Fukaya and Shigeki Odagiri and Kaneo Suzuki and Kohu Murohashi and Keiichiro Matsunaga and Hiroyuki Numata and Izumi Oyama and Shunichi Ishii and Masaaki Arakawa and Koichi Wada and Osamu Sekine and Nobuki Aoki and Kaoru Oyama and Atsuhiko Sato and Masahiko Okano and Wataru Sugiura and Akira Yamazaki and Takayoshi Watanabe and Toshihiko Takeuchi and Masahito Kato and Kunio Nanjo and Tatsuo Satake and Kenzo Takagi and Kenichi Yamaki and Hideo Gonda and Yasunobu Noda and Fumiyuki Kuze and Takuya Kurasawa and Takako Murayama and Eisaku Tanaka and Takakazu Sugita and Fumio Miki and Yoshiyasu Ikuno and Eiji Inoue and Akihito Murata and Shinichi Tanizawa and Kazuo Sakamoto and Akira Tahara and Yoshio Kawase and Kojiro Yasunaga and Seibun Yonezu and Nobuhiro Narita and Masayoshi Sawaki and Keiichi Mikasa and Rinzo Soejima and Yoshihito Niki and Yoshikazu Tasaka and Toshio Kishimoto and Toshiharu Matsushima and Michifumi Adachi and Osamu Kurimura and Hideo Sasaki and Hirofumi Fukuhara and Takao Sasaki and Yukio Matsumoto and Yoshiro Sawae and Atsushi Shinoda and Tsuneo Ishibashi and Masahiro Takamoto and Hozumi Yamada and Osamu Katoh and Kohei Hara and Masaki Hirota and Keizo Yamaguchi and Shigeru Kohno and Toshiaki Hayashi and Akira Yasuoka and Kazuo Sasayama and Makoto Ishizaki and Takashi Ide and Hiroko Nakazato and Oe Toshiyuki and Keizo Matsumoto and Atsushi Takahashi and Sukuro Araki and Masayuki Ando and Moritaka Suga and Kiyoshi Shima and Shinobu Takenaka and Yasutsugu Fukuda and Haruhiko Tokuomi and Masaru Nasu and Hideaki Shigeno and Jun Goto and Takayoshi Tashiro",

year = "1989",

doi = "10.11250/chemotherapy1953.37.1086",

language = "English",

volume = "37",

pages = "1086--1118",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

number = "8",

}

TY - JOUR

T1 - Comparative study on T-3262 (tosufloxacin tosilate) and ofloxacin in respiratory tract infection by double-blind method

AU - Fujimori, Ippei

AU - Saito, Akira

AU - Nakayama, Ichiro

AU - Tomisawa, Masumi

AU - Takebe, Kazuo

AU - Nakamura, Mitsuo

AU - Kawagishi, Takahiko

AU - Miyazawa, Tadashi

AU - Tamura, Toyokazu

AU - Endo, Katsumi

AU - Takishima, Tamotsu

AU - Mamune, Ruriko

AU - Konno, Kiyoshi

AU - Oizumi, Kotaro

AU - Aonuma, Seiichi

AU - Watanabe, Akira

AU - Tokue, Yutaka

AU - Hayashi, Izumi

AU - Okui, Shinji

AU - Fukui, Toshio

AU - Kato, Shinjiro

AU - Hosono, Osamu

AU - Abe, Toru

AU - Haga, Toshihiko

AU - Shishido, Harumi

AU - Kobayashi, Hiroyuki

AU - Kawai, Shin

AU - Takeda, Hiroaki

AU - Kawahira, Masahide

AU - Miyahara, Tadashi

AU - Shimada, Jingoro

AU - Kabe, Junzaburo

AU - Kudo, Koichiro

AU - Sakamoto, Yoshio

AU - Shimada, Kaoru

AU - Sano, Yasuyuki

AU - Miyamoto, Yasufumi

AU - Yoshimoto, Koji

AU - Ikemoto, Hideo

AU - Watanabe, Kazuyoshi

AU - Inagaki, Masayoshi

AU - Orimo, Hajime

AU - Fukuchi, Yoshinosuke

AU - Yamaoka, Minoru

AU - Honma, Mitsuo

AU - Kawai, Takashi

AU - Ajisawa, Atsushi

AU - Onaka, Akio

AU - Higashi, Fuyuhiko

AU - Arikawa, Kazumi

AU - Kato, Tatsuo

AU - Kuramoto, Miyoko

AU - Tanimoto, Hiroichi

AU - Nakata, Koichiro

AU - Chonabayashi, Naohiko

AU - Nakamori, Yoshitaka

AU - Nakatani, Tatsuo

AU - Inamatsu, Takashi

AU - Fukayama, Makiko

AU - Watanabe, Kentaro

AU - Koyama, Masaru

AU - Uzuka, Yoshio

AU - Irimajiri, Shoichiro

AU - Matsuoka, Yasuo

AU - Obana, Mitsuo

AU - Mitsui, Takeshi

AU - Okubo, Takao

AU - Ikeda, Hirotada

AU - Matsumura, Masanori

AU - Takahashi, Hiroshi

AU - Matsumoto, Fumio

AU - Sakurai, Iwao

AU - Fukaya, Kazufuto

AU - Odagiri, Shigeki

AU - Suzuki, Kaneo

AU - Murohashi, Kohu

AU - Matsunaga, Keiichiro

AU - Numata, Hiroyuki

AU - Oyama, Izumi

AU - Ishii, Shunichi

AU - Arakawa, Masaaki

AU - Wada, Koichi

AU - Sekine, Osamu

AU - Aoki, Nobuki

AU - Oyama, Kaoru

AU - Sato, Atsuhiko

AU - Okano, Masahiko

AU - Sugiura, Wataru

AU - Yamazaki, Akira

AU - Watanabe, Takayoshi

AU - Takeuchi, Toshihiko

AU - Kato, Masahito

AU - Nanjo, Kunio

AU - Satake, Tatsuo

AU - Takagi, Kenzo

AU - Yamaki, Kenichi

AU - Gonda, Hideo

AU - Noda, Yasunobu

AU - Kuze, Fumiyuki

AU - Kurasawa, Takuya

AU - Murayama, Takako

AU - Tanaka, Eisaku

AU - Sugita, Takakazu

AU - Miki, Fumio

AU - Ikuno, Yoshiyasu

AU - Inoue, Eiji

AU - Murata, Akihito

AU - Tanizawa, Shinichi

AU - Sakamoto, Kazuo

AU - Tahara, Akira

AU - Kawase, Yoshio

AU - Yasunaga, Kojiro

AU - Yonezu, Seibun

AU - Narita, Nobuhiro

AU - Sawaki, Masayoshi

AU - Mikasa, Keiichi

AU - Soejima, Rinzo

AU - Niki, Yoshihito

AU - Tasaka, Yoshikazu

AU - Kishimoto, Toshio

AU - Matsushima, Toshiharu

AU - Adachi, Michifumi

AU - Kurimura, Osamu

AU - Sasaki, Hideo

AU - Fukuhara, Hirofumi

AU - Sasaki, Takao

AU - Matsumoto, Yukio

AU - Sawae, Yoshiro

AU - Shinoda, Atsushi

AU - Ishibashi, Tsuneo

AU - Takamoto, Masahiro

AU - Yamada, Hozumi

AU - Katoh, Osamu

AU - Hara, Kohei

AU - Hirota, Masaki

AU - Yamaguchi, Keizo

AU - Kohno, Shigeru

AU - Hayashi, Toshiaki

AU - Yasuoka, Akira

AU - Sasayama, Kazuo

AU - Ishizaki, Makoto

AU - Ide, Takashi

AU - Nakazato, Hiroko

AU - Toshiyuki, Oe

AU - Matsumoto, Keizo

AU - Takahashi, Atsushi

AU - Araki, Sukuro

AU - Ando, Masayuki

AU - Suga, Moritaka

AU - Shima, Kiyoshi

AU - Takenaka, Shinobu

AU - Fukuda, Yasutsugu

AU - Tokuomi, Haruhiko

AU - Nasu, Masaru

AU - Shigeno, Hideaki

AU - Goto, Jun

AU - Tashiro, Takayoshi

PY - 1989

Y1 - 1989

N2 - We compared the clinical efficacy, safety and utility of T-3262 (tosufloxacin tosilate), a new derivative pyridonecarboxylic acid, with those of ofloxacin (OFLX) in patients with respiratory tract infection (RTI) by double-blind study. RTI included in the protocol were bacterial pneumonia and chronic respiratory tract infection. The drug was given orally for a fixed period of 14 days and the daily dosage was fixed at 450mg for T-3262 or 600mg for OFLX. The following results were obtained. 1. On the basis of committee judgement, the clinical efficacy rate in all cases was 82.9% for T-3262 and 82.5% for OFLX. No significant difference was observed between the two groups, not even in clinical efficacy when classified by type of disease. 2. The clinical efficacy rate judged by the doctors in charge was similar to that judged by the committee. 3. The bacteriological eradication rate of causative organisms judged by the committee was 78.6% for T-3262 and 85.1% for OFLX, without statistically significant difference. 4. With respect to the rate of improvement of clinical signs, symptoms and laboratory findings, T-3262 was superior to OFLX as to body temperature. 5. The incidence rate of side effects was 7.8% for T-3262 and 6.7% for OFLX, and there were no significant differences between the two groups. Abnormalities in laboratory findings, mainly slightly elevated serum transaminase and eosinophils, were not significantly different between the two groups. 6. The utility rate in all cases judged by the committee was 79.6% for T-3262 and 79.8% for OFLX. No significant difference between the two groups was noted. Even when classified by type of disease, there was no significant difference in utility between the two groups. 7. Neither was there any significant difference between the two groups in the utility rate when judged by the doctors in charge. 8. From our results, we consider both T-3262 (at a daily dose of 450 mg) and OFLX (at a daily dose of 600mg) to be highly useful antibacterial agents for the treatment of respiratory tract infections.

AB - We compared the clinical efficacy, safety and utility of T-3262 (tosufloxacin tosilate), a new derivative pyridonecarboxylic acid, with those of ofloxacin (OFLX) in patients with respiratory tract infection (RTI) by double-blind study. RTI included in the protocol were bacterial pneumonia and chronic respiratory tract infection. The drug was given orally for a fixed period of 14 days and the daily dosage was fixed at 450mg for T-3262 or 600mg for OFLX. The following results were obtained. 1. On the basis of committee judgement, the clinical efficacy rate in all cases was 82.9% for T-3262 and 82.5% for OFLX. No significant difference was observed between the two groups, not even in clinical efficacy when classified by type of disease. 2. The clinical efficacy rate judged by the doctors in charge was similar to that judged by the committee. 3. The bacteriological eradication rate of causative organisms judged by the committee was 78.6% for T-3262 and 85.1% for OFLX, without statistically significant difference. 4. With respect to the rate of improvement of clinical signs, symptoms and laboratory findings, T-3262 was superior to OFLX as to body temperature. 5. The incidence rate of side effects was 7.8% for T-3262 and 6.7% for OFLX, and there were no significant differences between the two groups. Abnormalities in laboratory findings, mainly slightly elevated serum transaminase and eosinophils, were not significantly different between the two groups. 6. The utility rate in all cases judged by the committee was 79.6% for T-3262 and 79.8% for OFLX. No significant difference between the two groups was noted. Even when classified by type of disease, there was no significant difference in utility between the two groups. 7. Neither was there any significant difference between the two groups in the utility rate when judged by the doctors in charge. 8. From our results, we consider both T-3262 (at a daily dose of 450 mg) and OFLX (at a daily dose of 600mg) to be highly useful antibacterial agents for the treatment of respiratory tract infections.

UR - http://www.scopus.com/inward/record.url?scp=0024440173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024440173&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.37.1086

DO - 10.11250/chemotherapy1953.37.1086

M3 - Article

AN - SCOPUS:0024440173

VL - 37

SP - 1086

EP - 1118

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

SN - 0009-3165

IS - 8

ER -

Comparative study on T-3262 (tosufloxacin tosilate) and ofloxacin in respiratory tract infection by double-blind method

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this